The Tumour Necrosis Factor Alpha -238 G --> A and -308 G --> A Promoter Polymorphisms Are Not Associated with Insulin Sensitivity and Insulin Secretion in Young Healthy Relatives of Type II Diabetic Patients
Overview
Affiliations
Aims/hypothesis: Tumour necrosis factor-alpha (TNF-alpha) is believed to influence skeletal muscle insulin resistance. Two G --> A transitions in the promoter region of TNF-alpha at position -238 and -308 have been identified that could play a part in transcriptional regulation of the gene. Insulin resistance is an independent familial trait that predicts the development of Type II (non-insulin-dependent) diabetes mellitus. We investigated the influence on insulin sensitivity and insulin secretion of both polymorphisms in a cohort of young healthy relatives of patients with Type II diabetes.
Methods: We examined 109 first-degree relatives of Caucasian patients with a history of Type II diabetes, who underwent extensive metabolical and anthropometrical phenotyping, and determined the TNF-alpha -238 and -308 G --> A promoter polymorphisms.
Results: For the -238 polymorphism, 3 probands (76.1%) were homozygous for the G-allele, 25 probands (22.9%) were heterozygous and 1 proband (0.9%) was homozygous for the A-allele. For the -308 polymorphism, 83 probands (76.1%) were homozygous for the G-allele, 24 probands (22.0%) were heterozygous and 2 probands (1.18%) were homozygous for the A-allele. Probands with and without the polymorphism did not differ in insulin sensitivity (p = 0.78), insulin-concentrations and C-peptide concentrations in oral glucose tolerance tests (p > 0.05).
Conclusions/interpretation: We could not detect an association between insulin sensitivity or insulin secretion and TNF-alpha promoter polymorphisms in our cohort. The polymorphisms occur at the same frequencies in probands with either low or high insulin sensitivity.
Salinas-Santander M, Leon-Cachon R, Cepeda-Nieto A, Sanchez-Dominguez C, Gonzalez-Zavala M, Gallardo-Blanco H Biomed Rep. 2016; 4(1):107-111.
PMID: 26870345 PMC: 4726844. DOI: 10.3892/br.2015.534.
Sefri H, Benrahma H, Charoute H, Lakbakbi El Yaagoubi F, Rouba H, Lyoussi B Mol Biol Rep. 2014; 41(9):5805-11.
PMID: 24952604 DOI: 10.1007/s11033-014-3454-5.
Dongiovanni P, Anstee Q, Valenti L Curr Pharm Des. 2013; 19(29):5219-38.
PMID: 23394097 PMC: 3850262. DOI: 10.2174/13816128113199990381.
Mustapic M, Hadzija M, Pavlovic M, Pavkovic P, Presecki P, Mrazovac D Metab Brain Dis. 2012; 27(4):507-12.
PMID: 22580620 DOI: 10.1007/s11011-012-9310-1.
Yu G, Ha E, Park S, Park J, Jang H, Bae J Inflamm Res. 2011; 60(12):1099-105.
PMID: 21904873 DOI: 10.1007/s00011-011-0372-z.